Welcome to our dedicated page for Ginkgo Bioworks Holdings SEC filings (Ticker: DNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about Ginkgo’s financial condition, capital markets activity, governance developments, and material events related to its biological product manufacturing and cell engineering platform.
Recent DNA SEC filings include multiple Forms 8-K. These current reports cover topics such as quarterly financial results, entry into a Sales Agreement for potential at-the-market offerings of Class A common stock, and corporate governance matters, including changes in executive responsibilities and the preliminary approval of a settlement of stockholder derivative actions. Each 8-K also confirms that Ginkgo’s Class A common stock is registered under Section 12(b) of the Exchange Act and trades on the New York Stock Exchange under the symbol DNA.
Investors reviewing Ginkgo Bioworks’ filings can use this page to locate quarterly earnings press releases furnished on Form 8-K, agreements related to equity issuance, and descriptions of legal or governance developments. Over time, the broader filing history may also include annual reports on Form 10-K, quarterly reports on Form 10-Q, and proxy statements that discuss topics such as business segments, risk factors, and corporate governance practices.
Stock Titan enhances this information by pairing real-time updates from EDGAR with AI-powered summaries that explain the key points of lengthy filings. Instead of reading entire documents line by line, users can quickly see the main themes, then drill into the original forms for details about Ginkgo Bioworks’ cell engineering and biosecurity activities, capital structure, and other disclosed matters.
Ginkgo Bioworks Holdings, Inc. (DNA) received an amended Schedule 13G/A from Baillie Gifford & Co, a Scotland-based investment adviser, reporting its ownership in the company’s Class A common stock as of 12/31/2025.
Baillie Gifford reports beneficial ownership of 2,391,649 Class A shares, representing 4.93% of the class. It has sole power to vote and dispose of all these shares, with no shared voting or dispositive power. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Ginkgo Bioworks.
Form 144 discloses that holder Austin Che intends to sell 2,200 Class A shares through Fidelity Brokerage Services LLC on or about 02/04/2026 on the NYSE, with an aggregate market value of
The shares to be sold were acquired via restricted stock vesting from the issuer on
Ginkgo Bioworks Holdings, Inc. Chief Financial Officer Steven P. Coen reported RSU vesting and a small share sale. On January 16, 2026, RSUs covering 587, 156, and 1,062 units were converted into the same number of Class A common shares at an exercise price of $0 per share, reflecting equity awards that had been vesting over time. After these conversions, he held 9,293 Class A shares directly. On January 20, 2026, he sold 972 Class A shares at $8.917 per share, leaving him with 8,321 shares. According to the footnotes, the sale was made to cover tax withholding obligations related to the vesting of restricted stock and RSUs and did not represent a discretionary trade.
Ginkgo Bioworks Holdings (symbol DNA) filed a notice of proposed sales of restricted stock under Rule 144. The filing covers a planned sale of 972 Class A shares through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of 8,667.23 and 48,523,595 Class A shares outstanding.
The 972 Class A shares were acquired on 01/16/2026 through restricted stock vesting from the issuer as compensation, with payment dated 01/16/2026. The notice also discloses that Steven Coen previously sold 736 Class A shares on 12/15/2025 for gross proceeds of 6,540.02.
A holder of Class A shares of DNA has filed a notice of proposed sale under Rule 144. The filing covers 2,200 Class A shares to be sold through Fidelity Brokerage Services LLC, with an indicated aggregate market value of 20,152.00. The shares are listed on the NYSE, and the approximate sale date given is 01/07/2026. These 2,200 shares were acquired on 10/19/2022 through restricted stock vesting from the issuer as compensation. The filing notes that there are 48,523,595 Class A shares outstanding. Over the prior three months, the same seller, Austin Che, reported three separate sales of 2,200 Class A shares each, with gross proceeds of 33,462.00, 18,700.00, and 20,988.00.
Ginkgo Bioworks Holdings, Inc. reported a leadership transition in its operating roles. Effective January 1, 2026, co‑founder Dr. Reshma Shetty will transition her Chief Operating Officer responsibilities to Chief Executive Officer Dr. Jason Kelly and executive Jennifer Wipf. Dr. Shetty will remain President, continue serving on the Board of Directors, and focus on expanding and using the company’s autonomous lab to deliver cell engineering service offerings, while Dr. Kelly will take on the principal operating officer policymaking duties.
Jennifer Wipf, previously Chief Commercial Officer and General Manager, Discovery Solutions and Manufacturing, will oversee operations functions such as day‑to‑day commercial operations, procurement, deployment, facilities and real estate, and people operations, reporting to Dr. Kelly. The changes keep Dr. Shetty in a substantial policymaking role while formalizing broader operating responsibilities for Dr. Kelly and Ms. Wipf.
Ginkgo Bioworks Holdings, Inc. reported insider equity transactions by a senior officer. On 12/12/2025, restricted stock units vested and were converted into 1,174 and 312 shares of Class A common stock, reflecting ongoing equity compensation. After these conversions, the officer directly held 8,224 Class A shares.
On 12/15/2025, 736 Class A shares were sold at $8.886 per share to satisfy tax withholding obligations tied to the vesting of restricted stock and restricted stock units. The company’s equity incentive plans allow these mandatory “sell to cover” transactions, which are described as non‑discretionary for the officer. Following the sale, the officer directly owned 7,488 Class A shares and continued to hold restricted stock units subject to multi‑year vesting schedules beginning May 1, 2024.
Steve Coen filed a notice of proposed sale of restricted stock for the company with ticker DNA. The filing covers a planned sale of 736 Class A shares through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 12/15/2025 and an aggregate market value of $6540.02. The table lists 48523595 Class A shares outstanding.
The shares to be sold were acquired on 12/12/2025 via restricted stock vesting from the issuer as compensation. The notice also reports that in the prior three months Steve Coen sold 5609 and 1312 Class A shares on 10/01/2025 and 10/17/2025, generating gross proceeds of $84135.00 and $17907.89. By signing, the seller represents he does not know any material adverse information about the issuer’s current and prospective operations that has not been publicly disclosed and acknowledges potential federal criminal penalties for intentional misstatements.
Ginkgo Bioworks insider plans another small Class A share sale. A holder has filed a notice to sell 2,200 shares of Class A common stock through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $20,988.00. The filing lists 48,523,595 Class A shares outstanding.
The seller, identified as Austin Che, acquired these shares through restricted stock vesting in October 2022 as compensation from the issuer. Over the past three months, the same seller reported three separate NYSE sales of 2,200 Class A shares each, with gross proceeds of $23,716.00, $33,462.00, and $18,700.00. The notice also includes a representation that the seller is not aware of undisclosed material adverse information about the company’s current or prospective operations.
Ginkgo Bioworks Holdings, Inc.: Cascade Investment, L.L.C. and William H. Gates III reported beneficial ownership of 3,621,636 Class A shares, representing 7.5% of the class. William H. Gates III may be deemed to beneficially own these shares as the sole member of Cascade. The filing date of event is 09/30/2025.
The reported amount includes 299,052 earn-out shares that vest in equal tranches if the stock trades at specified price thresholds for 20 of 30 consecutive trading days before September 16, 2026, as outlined in the merger agreement. The holders report sole voting and dispositive power over 3,621,636 shares and no shared power. The percentage is based on 48,523,595 shares outstanding as of October 31, 2025. The certification states the securities are not held to change or influence control.